Pharmacological profile of MEDI-551, a novel anti-CD19 antibody, in human CD19 transgenic mice
S Gallagher, S Turman, I Yusuf, A Akhgar, Y Wu… - International …, 2016 - Elsevier
B cell depletion therapy is beneficial for patients with B cell malignancies and autoimmune
diseases. CD19, a transmembrane protein, is expressed on a vast majority of normal and …
diseases. CD19, a transmembrane protein, is expressed on a vast majority of normal and …
Pharmacological profile of MEDI-551, a novel anti-CD19 antibody, in human CD19 transgenic mice
S Gallagher, S Turman, I Yusuf, A Akhgar, Y Wu… - International …, 2016 - infona.pl
B cell depletion therapy is beneficial for patients with B cell malignancies and autoimmune
diseases. CD19, a transmembrane protein, is expressed on a vast majority of normal and …
diseases. CD19, a transmembrane protein, is expressed on a vast majority of normal and …
Pharmacological profile of MEDI-551, a novel anti-CD19 antibody, in human CD19 transgenic mice.
S Gallagher, S Turman, I Yusuf, A Akhgar… - International …, 2016 - europepmc.org
B cell depletion therapy is beneficial for patients with B cell malignancies and autoimmune
diseases. CD19, a transmembrane protein, is expressed on a vast majority of normal and …
diseases. CD19, a transmembrane protein, is expressed on a vast majority of normal and …
Pharmacological profile of MEDI-551, a novel anti-CD19 antibody, in human CD19 transgenic mice
S Gallagher, S Turman, I Yusuf… - International …, 2016 - pubmed.ncbi.nlm.nih.gov
B cell depletion therapy is beneficial for patients with B cell malignancies and autoimmune
diseases. CD19, a transmembrane protein, is expressed on a vast majority of normal and …
diseases. CD19, a transmembrane protein, is expressed on a vast majority of normal and …